NeuroOne Medical Technologies Corporation announced the appointment of Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at Penumbra, Inc., a leading thrombectomy company, where he oversees long-range planning, financial planning and analysis, business development, and investor relations. His appointment brings significant medical technology industry experience and strategic insight to NeuroOne as the company advances its neurological disorder treatment technologies.
Prior to his role at Penumbra, Mills spent over two decades as a dedicated medical technology investment analyst. He served as Managing Director and head of the medical technology equity research practice at Canaccord Genuity for more than 13 years, where he conducted financial modeling, published research, and performed due diligence on numerous public and private companies in the sector. His analytical work earned him recognition as the #2 ranked Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.
Dave Rosa, CEO of NeuroOne, stated that Mills brings unparalleled experience and insights in medical technology from both corporate and investment perspectives. "Having known Jason since he was at Canaccord, I know he brings unparalleled and invaluable experience and insights in med-tech," Rosa said. "His firsthand knowledge of our industry, combined with his investment and capital markets expertise, will be a critical resource as we progress on our clinical and corporate goals."
Paul Buckman, Chairman of the Board of Directors, noted that Mills will serve on the Compensation and Nominating & Corporate Governance Committees while helping expand the company's reach in transforming neurological disorder diagnosis and treatment. NeuroOne is developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain from failed back surgeries. The company may also pursue applications for depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit https://nmtc1.com.
This board appointment matters because it strengthens NeuroOne's strategic direction during a critical growth phase in the competitive neurological treatment market. Mills' dual expertise as both a corporate executive at a successful medical technology company and a respected industry analyst provides NeuroOne with valuable perspective on market trends, investor expectations, and strategic partnerships. His experience at Penumbra, which focuses on innovative technologies for challenging medical conditions like ischemic stroke and pulmonary embolism, offers relevant insights for NeuroOne's development of neurological disorder solutions.
The implications extend to patients suffering from neurological conditions who may benefit from accelerated development of NeuroOne's technologies. Mills' capital markets expertise could help the company secure necessary funding for clinical trials and commercialization efforts, potentially bringing new treatment options to market more efficiently. For the medical technology industry, this appointment represents the growing importance of combining clinical innovation with sophisticated financial and strategic planning, particularly for companies addressing complex neurological disorders where development timelines are long and regulatory pathways are challenging.
